Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

WBP2 promotes BTRC mRNA stability to drive migration and invasion in triple-negative breast cancer via NF-κB activation.

Tytuł:
WBP2 promotes BTRC mRNA stability to drive migration and invasion in triple-negative breast cancer via NF-κB activation.
Autorzy:
Lim YX; Integrative Sciences and Engineering Programme, National University of Singapore, Singapore.; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Lin H; Integrative Sciences and Engineering Programme, National University of Singapore, Singapore.; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Chu T; Integrative Sciences and Engineering Programme, National University of Singapore, Singapore.; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.; Department of Biomedical Informatics, Yong Loo Lin School of Medicine, National University Health System, Singapore City, Singapore.
Lim YP; Integrative Sciences and Engineering Programme, National University of Singapore, Singapore.; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.; National University Cancer Institute, Singapore City, Singapore.
Źródło:
Molecular oncology [Mol Oncol] 2022 Jan; Vol. 16 (2), pp. 422-446. Date of Electronic Publication: 2021 Aug 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: 2017- : Hoboken, New Jersey : John Wiley & Sons, Inc.
Original Publication: Amsterdam : Elsevier
MeSH Terms:
Neoplasm Invasiveness*
Neoplasm Metastasis*
NF-kappa B/*metabolism
RNA, Messenger/*genetics
Trans-Activators/*physiology
Triple Negative Breast Neoplasms/*pathology
beta-Transducin Repeat-Containing Proteins/*genetics
Cell Line, Tumor ; DNA Copy Number Variations ; Female ; Humans ; Inflammation/metabolism ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/metabolism
References:
Oncotarget. 2017 Apr 6;8(35):58338-58352. (PMID: 28938560)
Cancer Manag Res. 2019 May 14;11:4471-4480. (PMID: 31191009)
PLoS One. 2020 Apr 30;15(4):e0232271. (PMID: 32353015)
Oncogene. 2020 Jun;39(24):4621-4635. (PMID: 32393834)
J Cell Physiol. 2010 Nov;225(3):682-91. (PMID: 20509143)
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3859-63. (PMID: 10097128)
Genes Dev. 1999 Feb 1;13(3):270-83. (PMID: 9990852)
Br J Cancer. 2003 Sep 15;89(6):1123-9. (PMID: 12966436)
Cold Spring Harb Perspect Biol. 2009 Nov;1(5):a000141. (PMID: 20066113)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
BMC Cancer. 2011 Apr 12;11:130. (PMID: 21486440)
J Biol Chem. 2000 Jan 28;275(4):2877-84. (PMID: 10644755)
Genes Dev. 2002 May 15;16(10):1167-81. (PMID: 12023297)
Nat Commun. 2017 Mar 28;8:14864. (PMID: 28348404)
Sci Rep. 2020 Feb 4;10(1):1804. (PMID: 32019974)
Adv Clin Exp Med. 2017 May-Jun;26(3):421-426. (PMID: 28791816)
Oncogene. 1999 Nov 22;18(49):6853-66. (PMID: 10602461)
FASEB J. 2011 Sep;25(9):3004-18. (PMID: 21642474)
PLoS One. 2010 Feb 05;5(2):e9060. (PMID: 20140206)
Mol Oncol. 2015 Feb;9(2):377-88. (PMID: 25306394)
Nat Commun. 2018 Apr 12;9(1):1423. (PMID: 29650964)
PLoS One. 2010 Dec 08;5(12):e14249. (PMID: 21170331)
J Biol Chem. 1997 Jul 4;272(27):17070-7. (PMID: 9202023)
Eur J Immunol. 2020 Oct;50(10):1468-1483. (PMID: 32459862)
Cell Oncol (Dordr). 2020 Feb;43(1):1-18. (PMID: 31900901)
Acta Pharmacol Sin. 2012 Apr;33(4):531-41. (PMID: 22426696)
Br J Cancer. 2010 Feb 16;102(4):639-44. (PMID: 20087353)
Br J Cancer. 2018 Jun 25;119:182-192. (PMID: 29937544)
Cancer Res. 2009 Sep 15;69(18):7357-65. (PMID: 19706770)
Breast Cancer Res. 2020 Jun 9;22(1):61. (PMID: 32517735)
Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7819-23. (PMID: 7644498)
Genome Med. 2018 Dec 3;10(1):94. (PMID: 30501643)
Biochem J. 2007 Apr 1;403(1):119-27. (PMID: 17125467)
Onco Targets Ther. 2019 Feb 18;12:1319-1331. (PMID: 30863098)
3 Biotech. 2020 Nov;10(11):485. (PMID: 33117626)
J Clin Oncol. 2009 Mar 10;27(8):1160-7. (PMID: 19204204)
J Biol Chem. 2018 Dec 28;293(52):20014-20028. (PMID: 30442712)
Cell Death Differ. 2011 Aug;18(8):1346-55. (PMID: 21311569)
Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877)
BMC Med Genet. 2019 Nov 9;20(1):175. (PMID: 31706287)
Life Sci Alliance. 2021 Jun 11;4(7):. (PMID: 34117091)
Cell Oncol (Dordr). 2016 Aug;39(4):353-63. (PMID: 27042827)
PLoS One. 2014 Nov 24;9(11):e113783. (PMID: 25419573)
Cell Death Dis. 2021 Apr 9;12(4):384. (PMID: 33837178)
Oncogene. 2011 Feb 3;30(5):600-10. (PMID: 20972459)
Nucleic Acids Res. 2009 Jan;37(Database issue):D674-9. (PMID: 18832364)
Oncol Lett. 2018 Mar;15(3):3820-3827. (PMID: 29467899)
Oncotarget. 2017 Dec 22;9(6):6771-6779. (PMID: 29467927)
Cancers (Basel). 2019 Jun 28;11(7):. (PMID: 31261762)
Cell Signal. 2011 Apr;23(4):641-7. (PMID: 21138764)
Nat Commun. 2019 Apr 8;10(1):1600. (PMID: 30962452)
Clin Cancer Res. 2019 Apr 15;25(8):2588-2600. (PMID: 30593516)
FASEB J. 2021 Feb;35(2):e21290. (PMID: 33475198)
Cancer Res. 2016 Nov 1;76(21):6278-6289. (PMID: 27578003)
Cell Signal. 2020 Feb;66:109466. (PMID: 31706018)
BMC Cancer. 2010 Oct 08;10:539. (PMID: 20932292)
Sci Rep. 2017 Feb 14;7:40005. (PMID: 28195222)
Cold Spring Harb Perspect Biol. 2010 Feb;2(2):a000166. (PMID: 20182612)
Nat Rev Immunol. 2018 May;18(5):309-324. (PMID: 29379212)
Front Biosci (Landmark Ed). 2012 Jun 01;17:2197-212. (PMID: 22652772)
FASEB J. 2018 Sep 5;:fj201801167RR. (PMID: 30183375)
Cancer Cell. 2006 Dec;10(6):515-27. (PMID: 17157791)
Cancer Cell Int. 2017 Dec 22;17:123. (PMID: 29299026)
Cell. 2018 Apr 5;173(2):291-304.e6. (PMID: 29625048)
Mol Cell. 2003 Jun;11(6):1445-56. (PMID: 12820959)
Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210)
Nat Commun. 2019 Dec 12;10(1):5679. (PMID: 31831737)
Cell. 2019 May 2;177(4):1035-1049.e19. (PMID: 31031003)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
J Biol Chem. 2001 Jul 20;276(29):27152-8. (PMID: 11375388)
Cell Physiol Biochem. 2018;48(5):1968-1982. (PMID: 30092563)
Oncogenesis. 2017 Sep 25;6(9):e383. (PMID: 28945218)
Nature. 2006 Jun 15;441(7095):898-901. (PMID: 16778892)
Cell Death Dis. 2018 Mar 1;9(3):347. (PMID: 29497031)
Mol Cell. 2011 Oct 21;44(2):304-16. (PMID: 22017876)
Infect Agent Cancer. 2016 Aug 20;11:45. (PMID: 27547238)
Int J Cancer. 2003 Jan 1;103(1):61-6. (PMID: 12455054)
Mol Cell. 2009 Jul 31;35(2):240-6. (PMID: 19647520)
Cell Death Dis. 2020 Aug 21;11(8):669. (PMID: 32820148)
J Cancer Res Clin Oncol. 2012 Jun;138(6):999-1009. (PMID: 22362301)
BMC Genomics. 2006 Apr 27;7:96. (PMID: 16643655)
Contributed Indexing:
Keywords: BTRC; NFKB; WBP2; invasion; migration; triple-negative breast cancer
Substance Nomenclature:
0 (BTRC protein, human)
0 (NF-kappa B)
0 (RNA, Messenger)
0 (Trans-Activators)
0 (WBP2 protein, human)
0 (beta-Transducin Repeat-Containing Proteins)
Entry Date(s):
Date Created: 20210701 Date Completed: 20220401 Latest Revision: 20220401
Update Code:
20240105
PubMed Central ID:
PMC8763649
DOI:
10.1002/1878-0261.13048
PMID:
34197030
Czasopismo naukowe
WW-domain-binding protein 2 (WBP2) is an oncogene that drives breast carcinogenesis through regulating Wnt, estrogen receptor (ER), and Hippo signaling. Recent studies have identified neoteric modes of action of WBP2 other than its widely recognized function as a transcriptional coactivator. Here, we identified a previously unexplored role of WBP2 in inflammatory signaling in breast cancer via an integrated proteogenomic analysis of The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA BRCA) dataset. WBP2 was shown to enhance the migration and invasion in triple-negative breast cancer (TNBC) cells especially under tumor necrosis factor alpha (TNF-α) stimulation. Molecularly, WBP2 potentiates TNF-α-induced nuclear factor kappa B (NF-κB) transcriptional activity and nuclear localization through aggrandizing ubiquitin-mediated proteasomal degradation of its upstream inhibitor, NF-κB inhibitor alpha (NFKBIA; also known as IκBα). We further demonstrate that WBP2 induces mRNA stability of beta-transducin repeat-containing E3 ubiquitin protein ligase (BTRC), which targets IκBα for ubiquitination and degradation. Disruption of IκBα rescued the impaired migratory and invasive phenotypes in WBP2-silenced cells, while loss of BTRC ameliorated WBP2-driven migration and invasion. Clinically, the WBP2-BTRC-IκBα signaling axis correlates with poorer prognosis in breast cancer patients. Our findings reveal a pivotal mechanism of WBP2 in modulating BTRC-IκBα-NF-κB pathway to promote TNBC aggressiveness.
(© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies